Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dotarem-enhanced MRA vs TOF MRA for Renal Arterial Disease
NCT00845702Phase 3Terminated
- Sponsor
- Guerbet
- Start
- Apr 2009
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gadoterate meglumine in renal artery stenosis (RAS), sponsored by Guerbet. Started Apr 2009; status: terminated.
02
Drugs
gadoterate meglumine
03
Conditions
renal artery stenosis (RAS)
Beyond the preview
Go deeper on NCT00845702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00845702.